From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...

With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...

Doctors and front-line workers are watching closely as HIV rates increase significantly in Alberta.An annual Alberta Health ...

The national HIV prevalence was 16.3% among adults aged 15 years and older, translating to an estimated 7.4 million adults ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...